Cyclacel Pharmaceuticals, Inc. (BGMS)
NASDAQ
Cyclacel Pharmaceuticals, Inc. Income Statement 2024–2025
| Dec 2025 | Dec 2024 | |
|---|---|---|
| Revenues | ||
| Revenue | 747,000 | 43,000 |
| Gross Profit | 138,000 | — |
| Profitability | ||
| Operating Income | -8.4M | -12.0M |
| EBITDA | -13.4M | -11.9M |
| Net Income | -3.0M | -11.2M |
| Per Share Data | ||
| EPS (diluted) | $-6.45 | $-501.60 |
| Shares Outstanding (dil.) | 2M | 0M |
Cyclacel Pharmaceuticals, Inc. Income Statement — FAQ
Cyclacel Pharmaceuticals, Inc. (BGMS) income statement over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BGMS's income statement history?
The chart and table above show Cyclacel Pharmaceuticals, Inc.'s income statement by year and by quarter, including the growth rate.